Elizabeth Tallett Joins Moderna’s Board of Directors
July 01 2020 - 8:00AM
Business Wire
Former President of Centocor and current Board
member of Anthem
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology
company pioneering messenger RNA (mRNA) therapeutics and vaccines
to create a new generation of transformative medicines for
patients, today announced that Elizabeth Tallett has joined its
Board of Directors. Ms. Tallett was also appointed to serve on the
Audit Committee of the Board. With the appointment of Ms. Tallett,
Dr. François Nader is stepping down from the Audit Committee.
“As Moderna approaches advanced stages of clinical development
across our programs, we are focused on strengthening our board with
industry leaders who understand the complexity of building
companies to make a positive impact on patients,” said Noubar
Afeyan, Co-Founder and Chairman of Moderna and Chief Executive
Officer of Flagship Pioneering. “Liz understands the opportunities
and challenges of growing healthcare companies and I am excited to
welcome her to the Board and to the Audit Committee.”
"I am delighted to be joining Moderna's board at such a unique
point in its history, as it rapidly moves towards commercialization
of its first products and starts to fulfill its mission of creating
a new class of life-saving mRNA medicines and vaccines,” said Ms.
Tallett. “I look forward to working with the board and management
of this dynamic and innovative company.”
“As we prepare for late-stage development of our COVID-19
vaccine and our CMV vaccine, we sought a director with diverse
experience leading companies poised for growth,” said Stéphane
Bancel, Chief Executive Officer of Moderna. “Liz’s extensive
experience leading healthcare companies of different sizes will be
an asset as we continue to scale and prepare for commercial launch.
I look forward to her guidance to help us to continue to build our
best possible version of Moderna.”
Ms. Tallett has spent more than 35 years in strategic leadership
and operational roles in worldwide biopharmaceutical and consumer
products industries. Her senior management positions include
Principal of Hunter Partners, President and CEO of Transcell
Technologies Inc., President of Centocor Pharmaceuticals and member
of the Parke-Davis Executive Committee.
In addition to serving on the Moderna Board of Directors, Ms.
Tallett is currently the Chair of Anthem, Inc. (NYSE: ANTM) and
Chair of the H.R. and Compensation Committee of the Principal
Financial Group (Nasdaq: PFG), Meredith Corp. Inc. (NYSE: MDP), and
Qiagen, Inc. (NYSE: QGEN). Until this year, Ms. Tallett was the
Lead Director for Principal, a role she also held at Coventry
Health Care, Inc. She has also served on the boards of Varian, Inc.
(NYSE: VAR), IntegraMed America Inc. (Nasdaq: INMD) and Varian
SemiConductor Associates, Inc. Ms. Tallett was a founding member of
the Biotechnology Council of New Jersey and is the Chair of the
board of trustees at Solebury School, PA. She was named a Financial
Times Outstanding Director of the year in 2015 and recognized as
one of the National Association of Corporate Directors (NACD)
Directorship 100 honorees in 2019.
Born and educated in England, Ms. Tallett graduated from
Nottingham University with a dual first class honours degree in
mathematics and economics.
About Moderna
Moderna is advancing messenger RNA (mRNA) science to create a
new class of transformative medicines for patients. mRNA medicines
are designed to direct the body’s cells to produce intracellular,
membrane or secreted proteins that have a therapeutic or preventive
benefit with the potential to address a broad spectrum of diseases.
Moderna’s platform builds on continuous advances in basic and
applied mRNA science, delivery technology and manufacturing,
providing the Company the capability to pursue in parallel a robust
pipeline of new development candidates. Moderna is developing
therapeutics and vaccines for infectious diseases, immuno-oncology,
rare diseases and cardiovascular diseases, independently and with
strategic collaborators.
Headquartered in Cambridge, Mass., Moderna currently has
strategic alliances for development programs with AstraZeneca PLC
and Merck & Co., Inc., as well as the Defense Advanced Research
Projects Agency (Nasdaq: DARPA), an agency of the U.S. Department
of Defense and the Biomedical Advanced Research and Development
Authority (BARDA), a division of the Office of the Assistant
Secretary for Preparedness and Response (ASPR) within the U.S.
Department of Health and Human Services (HHS). Moderna has been
named a top biopharmaceutical employer by Science for the past five
years. To learn more, visit www.modernatx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200701005518/en/
Media: Colleen Hussey Senior Manager, Corporate
Communications 617-335-1374 Colleen.Hussey@modernatx.com
Investors: Lavina Talukdar Head of Investor Relations
617-209-5834 Lavina.Talukdar@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Apr 2023 to Apr 2024